Showing results (71-80 of 609) with videos related to
Sort By:
Pageof 61
Urologic Oncology|December 30, 2008
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA)Stacy Loeb, Sara N Gashti, William J CatalonaThe Urologic Clinics of North America|February 16, 2010
The case for open radical prostatectomyEdward M Schaeffer, Stacy Loeb, Patrick C WalshThe Journal of Urology|September 28, 2013
Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancerAnnelies Vellekoop, Stacy Loeb, Yasin Folkvaljon, et al.European Urology Focus|July 29, 2019
Increasing Social Media Use in Urology: 2017 American Urological Association SurveyStacy Loeb, Todd Carrick, Christine Frey, et al.Urology|August 4, 2012
Novel technique for fragment removal after percutaneous management of large-volume neobladder calculiStacy Loeb, Michelle Jo Semins, Brian R MatlagaEbiomedicine|May 21, 2025
Germline testing for prostate cancer: current state and opportunities for enhanced accessStacy Loeb, Susan T Vadaparampil, Veda N GiriUrology|October 18, 2002
Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancerRobert W Veltri, M Craig Miller, Gerard J O'dowd, et al.Urology|May 12, 2004
Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c diseaseStephen J Freedland, Leslie A Mangold, Jonathan I Epstein, et al.Cancer|September 17, 2004
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysisPatrick J Bastian, Leslie A Mangold, Jonathan I Epstein, et al.BJU International|March 8, 2013
Prognostic Gleason grade grouping: data based on the modified Gleason scoring systemPhillip M Pierorazio, Patrick C Walsh, Alan W Partin, et al.Pageof 61